Total Funding
17
3
Total FundingSeed raised
Growth Score 17 in past quarter
-2 pts
Heat Score 3 in past quarter
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
141602
Convert Pharmaceuticals is a research and development company.
- Philippe Lambin: Chief Executive Officer & Co-Founder
- Brice Eeckhout: COOPast Role: The Medical Cloud Company, Co-Founder and MD
About the Company
Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance to
conventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs.
